For research use only, not for therapeutic use.
Imatinib mesylate（Cat No.:A000329）is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which drives chronic myeloid leukemia (CML). It also inhibits other kinases, such as c-Kit and PDGFR, making it effective in treating gastrointestinal stromal tumors (GIST) and some other cancers. By blocking these kinases, imatinib mesylate disrupts cellular signaling pathways essential for cancer cell proliferation and survival. Its introduction revolutionized the treatment of CML, turning a previously fatal disease into a manageable condition, and remains a cornerstone in targeted cancer therapy research.
| Catalog Number | A000329 |
| CAS Number | 220127-57-1 |
| Synonyms | CGP-57148B, ST-1571 Mesylate |
| Molecular Formula | C₂₉H₃₁N₇O.CH₄SO₃ |
| Purity | ≥95% |
| Target | Bcr-Abl |
| Solubility | >29.5mg/mL in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| InChI | InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4) |
| InChIKey | YLMAHDNUQAMNNX-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O |
| Reference | 1.Goldman, J. M., & Melo, J. V. (2003). Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment. <em>New England Journal of Medicine</em>, 349(15), 1451-1464. doi:10.1056/nejmra020777<br /> |
